Biocryst Pharmaceuticals Inc.
BCRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.5B
Close$
$7.62
23.2% downside
Current Fair Value
23.2% downsideOvervalued by 23.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.50 Billion |
|---|---|
| Enterprise Value | $2.76 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.26 |
| Beta | 0.55 |
| Outstanding Shares | 254,481,000 |
Return
| Return on Equity | 84.68% |
|---|---|
| Return on Assets | -68.96% |
| Return on Invested Capital | -88.67% |
Valuation & Multiples
| P/E Ratio | -6.83 |
|---|---|
| PEG | -0.47 |
| Price to Sales | 3.31 |
| Price to Book Ratio | -4.96 |
| Enterprise Value to Revenue | 2.94 |
| Enterprise Value to EBIT | -8.93 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | -0.93 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.15
Average shareholder expectationRevenue Estimate
$183.28 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$165.38 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2913▼ 16.08% |
|---|---|
| Total Calls | 1,838,013▲ 53.25% |
| Total Puts | 535,500▼ 1.26% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 109.89%▲ 7.08% |
|---|---|
| Total Invested | $2.89B▲ 21.78% |
| Investors Holding | 334▲ 19.00% |
ESG Score
No data
About Biocryst Pharmaceuticals Inc.
CEO: Jon Stonehouse